Sei Investments Co. Sells 2,454 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Sei Investments Co. trimmed its holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 5.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 46,208 shares of the company’s stock after selling 2,454 shares during the period. Sei Investments Co. owned about 0.06% of SpringWorks Therapeutics worth $1,741,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. First Horizon Advisors Inc. lifted its stake in shares of SpringWorks Therapeutics by 47.9% in the second quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company’s stock valued at $45,000 after buying an additional 383 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of SpringWorks Therapeutics in the second quarter valued at $123,000. CANADA LIFE ASSURANCE Co lifted its stake in shares of SpringWorks Therapeutics by 20.3% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,465 shares of the company’s stock valued at $220,000 after buying an additional 754 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of SpringWorks Therapeutics by 8.3% in the first quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock valued at $230,000 after buying an additional 358 shares in the last quarter. Finally, Financial Security Advisor Inc. bought a new position in shares of SpringWorks Therapeutics in the first quarter valued at $246,000.

SpringWorks Therapeutics Stock Up 2.5 %

Shares of NASDAQ:SWTX opened at $32.64 on Friday. The firm has a market capitalization of $2.42 billion, a PE ratio of -6.35 and a beta of 0.78. SpringWorks Therapeutics, Inc. has a twelve month low of $18.00 and a twelve month high of $53.92. The company has a 50-day moving average price of $36.62 and a two-hundred day moving average price of $40.07.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.58. The firm had revenue of $59.73 million during the quarter, compared to the consensus estimate of $34.42 million. During the same quarter last year, the business posted ($1.25) earnings per share. SpringWorks Therapeutics’s revenue was up 59732900.0% compared to the same quarter last year. Analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on SWTX shares. JPMorgan Chase & Co. increased their target price on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. HC Wainwright reiterated a “buy” rating and issued a $76.00 target price on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. Finally, Wedbush reiterated an “outperform” rating and issued a $77.00 target price (up previously from $75.00) on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics currently has an average rating of “Buy” and an average price target of $68.50.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.